The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...
Saphnelo, a human monoclonal antibody, is a type 1 interferon (INF) receptor antagonist that inhibits a key protein in the immune system called the IFNAR receptor. This protein acts like a transmitter ...
Saphnelo (anifrolumab-fnia) is a prescription drug used to treat systemic lupus erythematosus. The drug comes as an intravenous (IV) infusion. It’s usually given once every 4 weeks by a healthcare ...
People with lupus often need to use medicine to manage their symptoms. Although there are many oral medicines that treat lupus, some people with moderate to severe lupus may not get enough benefit ...
In the trial, 362 eligible patients were randomized (1:1) and received a fixed-dose intravenous infusion of 300mg SAPHNELO or placebo every four weeks. TULIP-2 assessed the effect of SAPHNELO in ...
AstraZeneca’s SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus ...
The U.S. Food and Drug Administration (FDA) approved Saphnelo to treat adults with moderate to severe systemic lupus erythematosus (SLE ) on August 2, 2021. SLE is the most common form of lupus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results